Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality.

Hematology/oncology clinics of North America - 1 Aug 2017

Sellar Rob, Losman Julie-Aurore

Abstract excerpt

Clonal myeloid disorders are characterized by genetic alterations that activate cytokine signaling pathways and stimulate cell proliferation. These activated signaling pathways have been extensively studied as potential therapeutic targets, and tyrosine kinase inhibitors have indeed had extraordinary success in treating BCR/ABL-positive chronic myeloiud leukemia. However, although inhibitors of other activated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Fusion Proteins, bcr-abl

Share to Molecular Targeted Therapy

Share to Myeloproliferative Disorders

Share to Oncogenes

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 28673388
DOI: 10.1016/j.hoc.2017.04.001

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality.PMID 28673388Read ↗

Targeted signal transduction therapies in myeloid malignancies.Semantic proximity Read ↗

Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.Semantic proximity Read ↗

Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.Semantic proximity Read ↗

Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.Semantic proximity Read ↗

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.Semantic proximity Read ↗

BCR-ABL-negative chronic myeloid leukemia.Semantic proximity Read ↗

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.Semantic proximity Read ↗

Oncogenic signaling: new insights and controversies from chronic myeloid leukemiaSemantic proximity Read ↗

Kinase drug discovery approaches in chronic myeloproliferative disorders.Semantic proximity Read ↗

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Therapeutic targets in chronic myeloid leukaemiaSemantic proximity Read ↗

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.